Evaxion Biotech A/s 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Evaxion A/S significantly reduced net losses and boosted cash reserves in 2025, driven by a landmark licensing agreement with MSD for its AI-designed vaccine candidate EVX-B3 and promising clinical data for EVX-01.
NASDAQ
20-F: Evaxion Biotech A/S Files 20-F Report: Details Financial Performance and Key Developments for 2024
Evaxion Biotech A/S releases its 20-F filing, outlining its financial results for the year ended December 31, 2024, and highlighting key operational and strategic updates.
NASDAQ
Evaxion Biotech A/S releases its 20-F filing, detailing its financial performance for the year ended December 31, 2023, and highlighting its strategic shift towards AI-driven vaccine development and partnerships.